COVID-AGE

Last updated 4th January 2022

Covid-age was developed to assist health professionals when advising workers in the UK on their personal vulnerability to COVID-19, and implications for their employment.  Vulnerability can be quantified as the probability of death should infection occur.  It varies according to age, sex, ethnicity, the presence of other health conditions (comorbidities), and immunity from vaccination or previous infection.  Covid-age summarises published evidence on the impacts of age, sex, ethnicity and comorbidities in the absence of vaccination or previous infection. It is intended for use as part of occupational health assessment of individuals’ fitness for work, and not in clinical treatment pathways.

WHAT DOES COVID-AGE MEAN?

An individual’s Covid-age is calculated by expressing the impacts of risk factors as added years of age that would carry a similar increase in vulnerability.  The values for each applicable risk factor are then added to the individual’s true age. This gives an estimate of the age of a healthy white man, who in the absence of vaccination or previous infection, would be expected to have similar vulnerability.

HOW SHOULD COVID-AGE BE USED?

When assessing a worker’s occupational risk from COVID-19, their Covid-age can be set alongside their history of vaccination and/or infection to derive an overall estimate of personal vulnerability.  That assessment can then be combined with knowledge about their job and the expected community prevalence of infection, to obtain an assessment of risk (for more detailed guidance, see section below on Management of occupational risks from COVID-19).

HOW DO I FIND A PERSON’S COVID-AGE?

The easy way is to enter risk factors into the online calculator below.

Alternatively, you can calculate Covid-age using Table 1 at the bottom of this page (see section below on Estimating Covid-age using tables).

Before using Covid-age, it is important to note the following caveats.

CAVEATS

Because each individual is different, Covid-age is not an exact measure of vulnerability.  It is an estimate consistent with the current balance of scientific evidence.

Some of the categories of comorbidity are broad-ranging, and within them, vulnerability may vary. The tool gives an overall average estimate of vulnerability, which may be individually tailored through clinical judgement of a suitably qualified health professional.

Some potentially relevant health problems are not covered by the tool, because insufficient evidence is available on them. Using clinical judgement, it may in some cases be reasonable to apply added years that have been estimated for another similar condition. For example, there is evidence that inflammatory bowel diseases and inflammatory skin diseases carry similar vulnerability to inflammatory joint diseases.

Covid-age does not assess risks from Covid-19 in pregnancy.  While there is evidence of increased vulnerability during pregnancy, it is not in a form that can be incorporated into the current risk model.  Moreover, the disease can impact adversely on obstetric outcomes as well as maternal health.  When assessing and managing occupational risks from Covid-19 during pregnancy, users should refer to https://www.rcog.org.uk/en/guidelines-research-services/guidelines/coronavirus-pregnancy/covid-19-virus-infection-and-pregnancy/ 

Covid-age is based on evidence relating to various comorbidities, but in most cases, their treatment has not been considered separately. The estimate of added years for a condition represents an average across the spectrum of treatment for that disease. This includes the effects of treatment with immunosuppressive medication, and it is not necessary to add further years of age in respect of such treatment.

The group ‘other immunosuppressive disorders’ refers to medical conditions that depress immune responses, and which are not included elsewhere in the calculator.  It does not cover immunosuppressive medication. Any immunological effects of diseases that are listed elsewhere in the calculator (e.g. diabetes, splenectomy) are covered by those categories. 

Calculations assume as a default that added years for different risk factors can be summed (i.e. that relative risks multiply). However, that assumption may not be accurate for all risk factors, especially when it leads to calculated Covid-ages greater than 85. The online calculator therefore presents Covid-ages in this upper range simply as >85. It does, however, show the years added for each risk factor so that clinicians can see the assumed impact of different conditions.

SOURCES OF EVIDENCE ON VULNERABILITY

Further details of the background evidence and methods can be found here: Methods at 211214

MANAGEMENT OF OCCUPATIONAL RISKS FROM COVID-19

CONTEXT

In managing occupational risks of Covid-19, employers must control exposure to the virus so far as is reasonably practicable, taking into account the possibility that some workers will be more vulnerable than others should they contract the disease.

Strategies may include changes to the way in which work is carried out, use of barriers and personal protective equipment (PPE), and in some cases, exclusion or redeployment of individuals who are more vulnerable. The need for selective exclusion/redeployment of vulnerable workers will depend on the likelihood of their contracting Covid-19 through their work, and on the extent of their personal vulnerability to severe illness should they get the disease.

The level of individual risk that is considered acceptable will depend on value judgements, which can differ from person to person, and it is therefore not possible to lay down hard and fast rules.  However, we here suggest an approach that may be a useful starting point for decision-making.

The approach entails first using Covid-age to assess the individual’s vulnerability to COVID-19 in the absence of previous infection or vaccination.  That assessment is then modified to account for any previous infection or vaccination.  Finally, a matrix is applied to guide decisions according to the nature of the job and local prevalence of infection.

VULNERABILITY LEVELS

It may be convenient to stratify vulnerability into ranges. We have used a lower bound of Covid-age 85 to define a stratum of ‘very high vulnerability’. In the absence of vaccination or previous infection, this may correspond to infection fatality rates in excess of around one in twenty, and could be considered equivalent to being ‘clinically extremely vulnerable’.

To define a second stratum of ‘high vulnerability’, we suggest a lower bound at Covid-age 70 (which in those with no vaccination or previous infection has carried an infection fatality rate of around one in a hundred). This corresponds approximately to the threshold for the Government’s category of ‘clinically vulnerable’.

To account for differences in vulnerability below that level, we suggest a further cut-point at Covid-age 50, which distinguishes ‘moderate vulnerability’ from ‘low vulnerability’.

Covid-age will determine the stratum of vulnerability to which an individual is initially assigned, but in some cases clinical judgement may indicate that a different stratum is appropriate because of individual circumstances.

ACCOUNTING FOR SPECIFIC IMMUNITY

Specific immunity from previous infection and/or vaccination may reduce both the risk of becoming infected by SARS-CoV-2 and personal vulnerability should infection occur. The level of protection will vary according to time interval(s) since infection/vaccination, number of vaccinations, type(s) of vaccine administered, and the variant(s) of the virus to which the individual is subsequently exposed. It may also differ in the presence of comorbidities, and particularly those which impair immune responses.

Currently available data do not allow detailed quantitative assessment of how reductions in risk differ according to these variables, or how they are apportioned between lower rates of infection and lower vulnerability once infection has occurred.  It appears, however, that on average among people of working age, previous infection or vaccination will provide protection in excess of 80% against mortality from variants of SARS-CoV-2 that are currently dominant in the UK.  Moreover, that protection will last for months or longer, and can be enhanced by further vaccination.

The table below shows relative risks corresponding to different levels of vaccine protection against death from Covid-19, and reductions in Covid-age that would give an equivalent reduction in risk.

Level of vaccine protection (%) against death from Covid-19	Relative risk of death from Covid-19	Reduction in Covid-age (years) that would give equivalent relative risk
97.5	0.025	36
95	0.05	29
90	0.1	22
85	0.15	18
80	0.2	16
75	0.25	13
70	0.3	12
65	0.35	10
60	0.4	9
50	0.5	7
40	0.6	5
30	0.7	3

We suggest that to account for reduced risk from vaccination, it would be reasonable in many cases to shift a previously infected/vaccinated individual down by one stratum of vulnerability – for example, from ‘very high’ to ‘high’ or from ‘high’ to ‘moderate’.

An exception might be individuals on immune suppressant medication or with conditions affecting immunity such as HIV or cancer, who may not respond so well to vaccines. Particularly in such cases, clinical judgement should be applied when considering adjustments to assessed vulnerability.

ACCOUNTING FOR VIRAL PREVALENCE

A major determinant of risk is local prevalence of infection by SARS-CoV-2, Other things being equal, in occupations that do not involve selective contact with people more likely to be carrying the virus (as occurs for example in healthcare), risk of exposure can be expected to vary in proportion to the local prevalence of infection.

A MATRIX FOR RISK MANAGEMENT

Based on the above considerations, we set out below a matrix combining what we know about vulnerability, immunity, and viral prevalence to classify individuals according to the type of work that they might reasonably undertake.  It should be viewed as a rough guide and tailored to account for special circumstances and the views of the worker.

Matrix guide for estimation of a worker’s overall risk pre-and post-vaccination

	Overall risk is very high, avoid this activity
	Overall risk is high, only undertake this activity if it is essential and cannot be avoided
	Overall risk is moderate, avoid if the activity is unnecessary
	Overall risk is low, no requirement for any additional adjustments or controls

 

ESTIMATING COVID-AGE USING TABLES

Use these tables by starting with the person’s actual age and then adding or subtracting years for each risk factor that applies, using Table 1 below.

First find their actual age in the top line of the table, then follow the column down to find the estimated impact (i.e. years to add or subtract from their actual age) for each risk factor that applies to that person. For example:

1. A healthy white woman, aged 40, has a Covid-age of (40-5) = 35 years
2. A white man aged 45, BMI 36 with severe asthma, has a Covid-age of (45+13+11) = 69 years.
3. An Asian woman aged 50 with Type 2 diabetes, unknown HbA1c, has a Covid-age of (50-5+5+20) = 70 years.

Whether a person’s Covid-age is obtained from the online calculator or using Table 1, minor modification may be warranted to account for the specific circumstances of the individual (e.g. the severity of relevant comorbidities). If you judge that to be appropriate, you should make the adjustment using your clinical judgement,

Table 1.  Vulnerability from risk factors expressed as equivalence to added years of age

True age (years)	20	21	22	23	24	25	26	27	28	29
Female sex	-5	-5	-5	-5	-5	-5	-5	-5	-5	-5
Ethnicity
Asian or Asian British	5	5	5	5	5	5	5	5	5	5
Black	7	7	7	7	7	7	7	7	7	7
Mixed	5	5	5	5	5	5	5	5	5	5
Other non-white	4	4	4	4	4	4	4	4	4	4
Body mass index (Kg/m2)
30-34.9	7	7	7	7	7	6	6	6	6	6
35-39.9	19	19	19	18	18	18	18	17	17	17
≥40	25	25	24	24	24	23	23	23	22	22
Hypertension	12	12	12	12	12	12	12	11	11	11
Heart failure	25	25	25	25	25	25	24	24	24	24
Other chronic heart disease	20	20	20	20	20	20	19	19	19	19
Cerebrovascular disease	17	17	17	16	16	16	16	16	16	16
Asthma
Mild	1	1	1	1	1	1	1	1	1	1
Severe	15	15	15	15	15	15	14	14	14	14
Other chronic respiratory disease	17	17	17	17	17	16	16	16	16	16
Diabetes
Type 1
HbA1≤58 mmol/mol in past year	24	24	24	24	24	24	23	23	23	23
HbA1>58 mmol/mol in past year	27	27	27	27	27	27	26	26	26	26
HbA1c unknown	29	29	29	29	29	28	28	28	28	28
Type 2 and other
HbA1≤58 mmol/mol in past year	21	21	21	21	21	20	20	20	20	20
HbA1>58 mmol/mol in past year	23	23	23	23	23	22	22	22	22	22
HbA1c unknown	22	22	22	22	22	21	21	21	21	21
Chronic kidney disease
Estimated GFR 30-60 mL/min	42	41	40	39	38	37	37	36	35	34
Estimated GFR < 30 mL/min	53	52	51	50	50	49	48	47	46	46
Non-haematological cancer
Diagnosed <1 year ago	34	33	33	32	32	31	31	30	30	29
Diagnosed 1-4.9 years ago	25	25	25	24	24	24	23	23	22	22
Diagnosed ≥5 years ago	18	18	18	18	17	17	17	16	16	16
Haematological malignancy
Diagnosed <1 year ago	33	33	32	32	32	32	31	31	31	31
Diagnosed 1-4.9 years ago	32	31	31	31	30	30	30	29	29	29
Diagnosed ≥5 years ago	21	21	21	21	21	20	20	20	20	20
Liver disease	32	31	31	30	30	29	29	28	28	27
Chronic neurological disease other than stroke or dementia*	23	23	22	22	22	22	22	22	22	22
Organ transplant	25	25	24	24	24	24	24	24	24	24
Spleen diseases†	14	14	13	13	13	13	13	13	13	13
Rheumatoid/lupus/psoriasis	2	2	2	2	2	2	2	2	2	2
Other immunosuppressive condition‡	30	30	29	29	28	28	27	27	26	26

True age (years)	30	31	32	33	34	35	36	37	38	39
Female sex	-5	-5	-5	-5	-5	-5	-5	-5	-5	-5
Ethnicity
Asian or Asian British	5	5	5	5	5	5	5	5	5	5
Black	7	7	7	7	7	7	7	7	7	7
Mixed	5	5	5	5	5	5	5	5	5	5
Other non-white	4	4	4	4	4	4	4	4	4	4
Body mass index (Kg/m2)
30-34.9	6	6	6	6	6	6	6	6	5	5
35-39.9	17	16	16	16	16	15	15	15	15	15
≥40	22	21	21	21	20	20	19	19	19	18
Hypertension	11	11	11	11	10	10	10	10	10	10
Heart failure	24	23	23	23	22	22	22	22	21	21
Other chronic heart disease	19	18	18	18	17	17	17	17	16	16
Cerebrovascular disease	16	16	16	16	16	16	16	15	15	15
Asthma
Mild	1	1	1	1	1	1	1	1	1	1
Severe	14	14	14	13	13	13	13	13	12	12
Other chronic respiratory disease	16	15	15	15	15	15	14	14	14	14
Diabetes
Type 1
HbA1≤58 mmol/mol in past year	23	23	22	22	22	22	22	21	21	21
HbA1>58 mmol/mol in past year	26	26	25	25	25	25	25	25	24	24
HbA1c unknown	28	28	28	27	27	27	27	27	26	26
Type 2 and other
HbA1≤58 mmol/mol in past year	20	20	20	19	19	19	19	19	19	19
HbA1>58 mmol/mol in past year	22	22	22	21	21	21	21	21	21	21
HbA1c unknown	21	21	21	21	21	21	21	21	20	20
Chronic kidney disease
Estimated GFR 30-60 mL/min	33	32	32	31	30	29	28	27	26	26
Estimated GFR < 30 mL/min	45	44	44	43	42	41	40	39	38	37
Non-haematological cancer
Diagnosed <1 year ago	29	28	28	27	27	26	26	25	25	24
Diagnosed 1-4.9 years ago	22	21	21	21	20	20	19	19	18	18
Diagnosed ≥5 years ago	15	15	15	14	14	13	13	12	12	11
Haematological malignancy
Diagnosed <1 year ago	30	30	30	30	29	29	29	29	28	28
Diagnosed 1-4.9 years ago	28	28	28	27	27	27	26	26	25	25
Diagnosed ≥5 years ago	20	19	19	19	19	18	18	18	18	17
Liver disease	27	26	26	25	25	24	24	23	23	22
Chronic neurological disease other than stroke or dementia*	22	22	21	21	21	21	21	21	21	20
Organ transplant	23	23	23	23	23	23	22	22	22	22
Spleen diseases†	13	13	13	12	12	12	12	12	12	12
Rheumatoid/lupus/psoriasis	2	2	2	2	2	2	2	2	2	2
Other immunosuppressive condition‡	25	25	24	24	23	23	22	22	21	21

True age (years)	40	41	42	43	44	45	46	47	48	49
Female sex	-5	-5	-5	-5	-5	-5	-5	-5	-5	-5
Ethnicity
Asian or Asian British	5	5	5	5	5	5	5	5	5	5
Black	7	7	7	7	7	7	7	7	7	7
Mixed	5	5	5	5	5	5	5	5	5	5
Other non-white	4	4	4	4	4	4	4	4	4	4
Body mass index (Kg/m2)
30-34.9	5	5	5	5	5	5	5	4	4	4
35-39.9	14	14	14	14	13	13	13	13	12	12
≥40	18	17	17	17	16	16	16	15	15	14
Hypertension	9	9	9	9	9	8	8	8	8	8
Heart failure	21	20	20	20	19	19	19	18	18	18
Other chronic heart disease	16	15	15	15	14	14	14	13	13	13
Cerebrovascular disease	15	15	15	15	15	15	15	14	14	14
Asthma
Mild	1	1	1	1	1	1	1	1	1	1
Severe	12	12	12	11	11	11	11	10	10	10
Other chronic respiratory disease	14	13	13	13	13	13	13	12	12	12
Diabetes
Type 1
HbA1≤58 mmol/mol in past year	21	21	20	20	20	20	20	19	19	18
HbA1>58 mmol/mol in past year	24	24	24	23	23	23	23	22	22	22
HbA1c unknown	26	26	25	25	25	25	24	24	24	23
Type 2 and other
HbA1≤58 mmol/mol in past year	19	18	18	18	18	18	17	17	17	16
HbA1>58 mmol/mol in past year	21	20	20	20	20	20	19	19	19	18
HbA1c unknown	20	20	20	20	20	20	19	19	19	18
Chronic kidney disease
Estimated GFR 30-60 mL/min	25	24	23	22	21	20	19	19	18	18
Estimated GFR < 30 mL/min	36	35	35	34	33	33	32	32	31	30
Non-haematological cancer
Diagnosed <1 year ago	24	23	23	22	22	21	21	20	20	19
Diagnosed 1-4.9 years ago	18	17	17	16	16	16	15	15	14	13
Diagnosed ≥5 years ago	11	11	10	10	10	9	9	9	8	8
Haematological malignancy
Diagnosed <1 year ago	28	28	27	27	27	26	26	26	25	25
Diagnosed 1-4.9 years ago	25	24	24	23	23	22	22	22	22	22
Diagnosed ≥5 years ago	17	17	17	16	16	16	15	15	14	14
Liver disease	22	21	21	20	20	19	19	18	17	17
Chronic neurological disease other than stroke or dementia*	20	20	20	20	20	20	19	19	19	19
Organ transplant	22	22	21	21	21	21	21	20	20	20
Spleen diseases†	11	11	11	11	11	11	10	10	10	10
Rheumatoid/lupus/psoriasis	2	2	2	2	2	2	2	2	2	2
Other immunosuppressive condition‡	20	20	19	19	18	17	17	16	16	15

True age (years)	50	51	52	53	54	55	56	57	58	59
Female sex	-5	-5	-5	-5	-5	-5	-5	-5	-5	-5
Ethnicity
Asian or Asian British	5	5	5	5	5	5	5	5	5	5
Black	7	7	7	7	7	7	7	7	7	7
Mixed	5	5	5	5	5	5	5	5	5	5
Other non-white	4	4	4	4	4	4	4	4	4	4
Body mass index (Kg/m2)
30-34.9	4	4	4	3	3	3	3	3	3	3
35-39.9	12	11	11	11	10	10	10	10	9	9
≥40	14	14	13	13	12	12	12	11	11	11
Hypertension	7	7	7	7	7	6	6	6	5	5
Heart failure	17	17	17	16	16	16	15	15	14	14
Other chronic heart disease	13	12	12	12	12	11	11	10	10	9
Cerebrovascular disease	14	14	14	13	13	13	13	13	12	12
Asthma
Mild	1	1	1	1	1	1	1	1	1	1
Severe	9	9	9	9	8	8	8	7	7	7
Other chronic respiratory disease	12	12	11	11	11	11	10	10	10	9
Diabetes
Type 1
HbA1≤58 mmol/mol in past year	18	18	17	17	16	16	16	15	15	14
HbA1>58 mmol/mol in past year	21	21	20	20	19	19	19	18	18	17
HbA1c unknown	23	23	22	22	21	21	20	20	19	19
Type 2 and other
HbA1≤58 mmol/mol in past year	16	16	15	15	14	14	14	13	13	12
HbA1>58 mmol/mol in past year	18	18	17	17	16	16	16	15	15	14
HbA1c unknown	18	18	17	17	16	16	16	15	15	14
Chronic kidney disease
Estimated GFR 30-60 mL/min	17	16	16	15	14	14	13	13	12	11
Estimated GFR < 30 mL/min	30	29	28	28	27	26	26	25	24	23
Non-haematological cancer
Diagnosed <1 year ago	19	18	18	17	16	16	15	15	14	14
Diagnosed 1-4.9 years ago	13	12	11	11	10	10	9	9	8	8
Diagnosed ≥5 years ago	8	7	7	7	6	6	6	5	5	4
Haematological malignancy
Diagnosed <1 year ago	24	24	23	23	22	22	21	21	20	20
Diagnosed 1-4.9 years ago	21	21	21	21	20	20	20	19	19	18
Diagnosed ≥5 years ago	13	12	12	11	11	10	10	10	9	9
Liver disease	16	15	15	14	14	13	13	12	12	11
Chronic neurological disease other than stroke or dementia*	18	18	18	18	17	17	17	16	16	16
Organ transplant	19	19	19	18	18	18	17	17	16	16
Spleen diseases†	9	9	9	8	8	8	8	7	7	7
Rheumatoid/lupus/psoriasis	2	2	2	2	2	2	2	2	2	2
Other immunosuppressive condition‡	15	15	14	14	13	13	13	12	12	11

True age (years)	60	61	62	63	64	65	66	67	68	69
Female sex	-5	-5	-5	-5	-5	-5	-5	-5	-5	-5
Ethnicity
Asian or Asian British	5	5	5	5	5	5	5	5	5	5
Black	7	7	7	7	7	7	7	7	7	7
Mixed	5	5	5	5	5	5	5	5	5	5
Other non-white	4	4	4	4	4	4	4	4	4	4
Body mass index (Kg/m2)
30-34.9	3	2	2	2	2	2	2	2	2	2
35-39.9	9	8	8	8	7	7	7	6	6	5
≥40	10	10	10	9	9	9	8	8	7	7
Hypertension	5	5	4	4	4	3	3	3	2	2
Heart failure	13	13	12	12	11	11	11	10	10	10
Other chronic heart disease	9	8	8	7	7	6	6	5	5	5
Cerebrovascular disease	12	12	12	11	11	11	11	11	10	10
Asthma
Mild	1	1	1	1	1	1	1	1	1	1
Severe	6	6	5	5	4	4	4	4	3	3
Other chronic respiratory disease	9	9	8	8	8	7	7	7	7	7
Diabetes
Type 1
HbA1≤58 mmol/mol in past year	14	13	13	12	12	11	11	11	10	10
HbA1>58 mmol/mol in past year	17	16	16	15	15	14	14	14	13	13
HbA1c unknown	18	18	17	17	16	16	15	15	14	14
Type 2 and other
HbA1≤58 mmol/mol in past year	12	11	11	10	10	9	9	8	8	7
HbA1>58 mmol/mol in past year	14	13	13	12	12	11	11	11	10	10
HbA1c unknown	14	13	13	12	12	11	11	11	10	10
Chronic kidney disease
Estimated GFR 30-60 mL/min	11	10	9	9	8	8	7	7	6	6
Estimated GFR < 30 mL/min	23	22	22	21	20	20	19	19	18	18
Non-haematological cancer
Diagnosed <1 year ago	13	13	12	12	11	11	10	10	9	9
Diagnosed 1-4.9 years ago	8	7	7	7	6	6	6	5	5	4
Diagnosed ≥5 years ago	4	3	3	2	2	1	1	1	1	0
Haematological malignancy
Diagnosed <1 year ago	19	19	18	17	17	16	16	15	15	14
Diagnosed 1-4.9 years ago	18	17	17	16	16	15	15	14	14	13
Diagnosed ≥5 years ago	9	8	8	8	7	7	7	7	6	6
Liver disease	11	10	10	9	9	8	8	7	7	6
Chronic neurological disease other than stroke or dementia*	16	15	15	15	14	14	14	14	13	13
Organ transplant	15	15	14	14	13	13	12	12	11	11
Spleen diseases†	6	6	6	5	5	5	5	4	4	3
Rheumatoid/lupus/psoriasis	2	2	2	2	2	2	2	2	2	2
Other immunosuppressive condition‡	11	11	10	10	9	9	9	8	8	7

True age (years)	70	71	72	73	74	75
Female sex	-5	-5	-5	-5	-5	-5
Ethnicity
Asian or Asian British	5	5	5	5	5	5
Black	7	7	7	7	7	7
Mixed	5	5	5	5	5	5
Other non-white	4	4	4	4	4	4
Body mass index (Kg/m2)
30-34.9	2	1	1	1	1	1
35-39.9	5	5	4	4	3	3
≥40	7	6	6	5	5	5
Hypertension	2	1	1	0	0	0
Heart failure	9	9	9	8	8	8
Other chronic heart disease	4	4	4	3	3	3
Cerebrovascular disease	10	10	9	9	9	9
Asthma
Mild	1	1	1	1	1	1
Severe	3	3	2	2	2	2
Other chronic respiratory disease	6	6	6	6	6	6
Diabetes
Type 1
HbA1≤58 mmol/mol in past year	10	9	9	8	8	8
HbA1>58 mmol/mol in past year	13	12	12	12	11	11
HbA1c unknown	14	13	13	12	12	12
Type 2 and other
HbA1≤58 mmol/mol in past year	7	6	6	6	5	5
HbA1>58 mmol/mol in past year	9	9	9	8	8	8
HbA1c unknown	9	9	9	8	8	7
Chronic kidney disease
Estimated GFR 30-60 mL/min	5	5	4	4	3	3
Estimated GFR < 30 mL/min	17	17	16	16	15	15
Non-haematological cancer
Diagnosed <1 year ago	9	8	8	8	7	7
Diagnosed 1-4.9 years ago	4	3	3	3	2	2
Diagnosed ≥5 years ago	0	0	0	0	0	0
Haematological malignancy
Diagnosed <1 year ago	14	13	13	12	12	11
Diagnosed 1-4.9 years ago	13	12	12	11	11	11
Diagnosed ≥5 years ago	6	6	5	5	5	5
Liver disease	6	6	5	5	4	4
Chronic neurological disease other than stroke or dementia*	13	13	12	12	12	12
Organ transplant	10	10	9	9	8	8
Spleen diseases†	3	2	2	1	1	0
Rheumatoid/lupus/psoriasis	2	2	2	2	2	2
Other immunosuppressive condition‡	7	7	6	6	5	5

*Chronic neurological disease other than stroke or dementia includes motor neurone disease, myasthenia gravis, multiple sclerosis, Parkinson’s disease, cerebral palsy, quadriplegia, hemiplegia and progressive cerebellar disease.

†Spleen diseases include splenectomy, or spleen dysfunction (e.g. from sickle cell disease).

‡Other immunosuppressive condition includes HIV, conditions inducing permanent immunodeficiency (ever diagnosed), aplastic anaemia, and temporary immunodeficiency recorded within the past year.